Allotex Announces Commencement of Final Phase of Presbyopia Clinical Trials

BOSTON--(BUSINESS WIRE)--Allotex, a Boston based private company developing the TransForm Corneal Allograft (TCA) for the treatment of presbyopia (reading glasses) and hyperopia (far sightedness), is pleased to report that over 50 eyes have been treated in the first phase of its clinical trials. The TCA is created using natural human corneal tissue that has been shaped using high precision patented and proprietary technology. These shaped lenticules are placed in the patient’s natural cornea wi

Full Story →